PacBio To Launch New Gene-Sequencing Systems

Pacific BioSciences of California Inc PACB announced the launch of the Revio long-read sequencing system.
The company said its new Revio long-read sequencing system, with a list price of $779,000, offers a 15-fold increase in throughput, enabling customers to sequence up to 1,300 whole human genomes per year for less than $1,000 per genome.
PacBio said its HiFi technology could be used for large studies in human genetics, cancer research, agricultural genomics, and more.
Revio will deliver shorter run times and a 15-fold increase in HiFi data.
"By being able to see more of the genome, you can uncover more answers," PacBio Chief Executive Officer Christian Henry told Reuters.
The company is also entering the "short-read" sequencing market with external beta testing of its Onso system.
PacBio expects to begin taking orders for Onso in Q1 of 2023 and expects to begin shipments of the system in 1H of 2023 upon completion of the external beta program.
Onso is anticipated to deliver 500 million reads per run and offer 200 and 300-cycle kits enabling paired- and single-end reads, at a list price of $259,000 per system.
"What you're looking for in those diagnostic tests are needles in a haystack. You're trying to find that one mutated piece of DNA that could be an indication of having early cancer," Henry said.
Price Action: PACB shares closed 9.44% higher at $8.23 on Tuesday.